Literature DB >> 12269945

Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases.

S Kobayashi1, S Inokuma, K Setoguchi, H Kono, K Abe.   

Abstract

BACKGROUND: A definite threshold of the peripheral blood eosinophile count that indicates the presence of hypereosinophilia-associated diseases has not yet been determined.
METHODS: The threshold eosinophile count at which cases of hypereosinophilia-associated diseases (n = 25) can be differentiated from those of bronchial asthma (n = 101) was determined. Then, the incidences of eosinophile counts greater than 1.0 x 10(9)/l or the threshold level, were studied by analysis of 43,805 samples sent to the laboratory, and the diseases associated with the increased counts were determined.
RESULTS: The eosinophile count in cases of hypereosinophilia-associated diseases and in those of bronchial asthma were 10.967 +/- 1.680 x 10(9)/l and 0.574 +/- 0.045 x 10(9)/l, respectively (P < 0.001); the threshold was 2.052 x 10(9)/l. The percentages of samples with an eosinophile count of more than 1.0 x 10(9)/l and 2.052 x 10(9)/l were 0.6% and 0.1%, respectively; the latter comprised of 41 samples from 24 patients including eight with hypereosinophilia-associated diseases. The patients with hypereosinophilia-associated diseases had a significantly higher count, and a higher incidence of counts of more than 2.052 x 10(9)/l, than others, including patients with malignancies and symptoms conventionally referred as "atopic diseases".
CONCLUSION: Hypereosinophilia-associated diseases are associated with a very high eosinophile count of more than 2.052 x 10(9)/l, which was observed rarely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269945     DOI: 10.1034/j.1398-9995.2002.23479.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

Review 1.  A case of hypereosinophilic syndrome presenting with intractable gastric ulcers.

Authors:  Tae Young Park; Chang Hwan Choi; Suh Yoon Yang; In Soo Oh; In-Do Song; Hyun Woong Lee; Hyung Joon Kim; Jae Hyuk Do; Sae Kyung Chang; Ah Ra Cho; Young Joo Cha
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

2.  Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results.

Authors:  Alessandro Vinciguerra; Andrea Rampi; Mona-Rita Yacoub; Moreno Tresoldi; Umberto Tanzini; Mario Bussi; Matteo Trimarchi
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-21       Impact factor: 3.236

3.  Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance.

Authors:  Grzegorz Helbig; Marek Hus; Tomasz Francuz; Joanna Dziaczkowska-Suszek; Anna Soja; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

4.  Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis.

Authors:  Naomi Tsurikisawa; Chiyako Oshikata; Takahiro Tsuburai; Satoshi Sugano; Yoko Nakamura; Takuya Shimoda; Shunpei Tamama; Ken Adachi; Ayako Horita; Ikuo Saito; Hiroshi Saito
Journal:  BMC Immunol       Date:  2015-12-29       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.